Source comparison
PT-141 Safety Studies: Cardiovascular, Hormonal, and Hepatic Data Comparison
Cardiovascular Transient systolic BP increase 4–8 mmHg in 7% of subjects; resolved within 4 hours MC4R activation increases sympathetic tone transiently before nitric oxide-mediated vasodilation dominates No sustained hypertension or cardiovascular events repo
This comparison does not assign a generated winner or score.
- Cardiovascular
- Transient systolic BP increase 4–8 mmHg in 7% of subjects; resolved within 4 hours
- MC4R activation increases sympathetic tone transiently before nitric oxide-mediated vasodilation dominates
- No sustained hypertension or cardiovascular events reported in VAERS through 2024
- Exclude subjects with uncontrolled hypertension (≥160/100 mmHg); avoid use with PDE5 inhibitors within 24 hours due to additive vasodilatory effect
- Gastrointestinal
- Nausea in 40% (vs 13% placebo), peak 30–60 minutes post-injection
- Area postrema melanocortin receptor activation triggers emetic cascade
- Nausea remains most common AE in post-market reports; no cases of persistent emesis requiring intervention
- Self-limiting in 92% of cases; anti-emetics (ondansetron 4mg sublingual) mitigate if pre-dosed 30 minutes before injection
- Dermatologic
- Flushing in 20%, injection site reactions in 3%
- Nitric oxide-induced peripheral vasodilation; local histamine release at injection site
- No severe dermatologic reactions (Stevens-Johnson, DRESS) reported
- Flushing is pharmacological confirmation of melanocortin receptor engagement. Not an allergic response
- Hepatic
- ALT/AST elevation >3× ULN in <1%; resolved spontaneously
- Not definitively established. Possible transient hepatocellular stress
- No cases of drug-induced liver injury (DILI) meeting Hy's Law criteria reported through 2024
- Monitor liver enzymes if using >24 weeks continuously; discontinue if ALT/AST >5× ULN
- Hormonal
- No significant change in testosterone, LH, FSH, prolactin at 24 weeks
- Melanocortin receptors do not directly modulate HPG axis signaling
- No endocrine dysfunction reports in post-market data
- Does not suppress endogenous testosterone or alter fertility markers
- Bottom Line
- PT-141 safety studies confirm a tolerable adverse event profile for episodic use at 1.75mg SC in cardiovascularly healthy subjects. The primary safety concern is transient blood pressure elevation, which is self-limiting and mechanism-based rather than toxicological. Long-term (>24 weeks) and higher-dose safety remains formally undocumented.